Research Article

Modeling Drug-Carrier Interaction in the Drug Release from Nanocarriers

Table 1

Parameter estimates for simulations in Figure 3.

Drug/CarrieraMechanismsVariablesModel parametersb
(10−21 J)

1 mol% PEG0.494M0.014M−0.97
CFTSL [24]PEG addition3 mol% PEG1.568M0.026M0.83
4 mol% PEG1.273M0.039M2.18
10 mol% PEG2.785M0.089M4.77)

Vera-FBS2.268H0.092H4.71
Vera and Dox liposome [25]SerumVera-HBS1.912H0.096H3.88
Dox-FBS1.670H0.0037H−10.4
Dox-HBS1.706H0.0056H−12.6
Vera-in vivo4.561H0.08H11.5
Lipid membraneVera-MLV3.360H0.04H10.2
Dox-in vivo0.212H0.008H−1.22
Dox-MLV1.387H0.005H−2.32)

pH 2.00.028H
AmiodaroneLNC [26]pHpH 3.00.032H0.011H4.52
pH 4.00.033H0.006H3.49
pH 5.50.033H0.004H−0.86
pH 7.40.265H0.003H−9.35)

BSAPLLA [29]Molecular weight16,0000.719H0.025H0.41
51,0000.754H0.02H−3.3)

IndomethacinPECL [27]CoatingPLL-coated0.0182M0.202M11.8
uncoated0.0156M0.203M11.8

aCF: carboxylfluorescein; TSL: thermosensitive liposome; Vera: verapamil; Dox: doxorubicin; FBS: fetal bovine serum; HBS: Hepes buffered saline; BSA: bovine serum albumin; PLLA: poly(L-lactide); PECL: poly-ε-caprolactone.
b and have different units in difference cases: M: minute−1 and H: hour−1.